Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).

Article  PubMed  Google Scholar 

Khan, S. S. et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 148, 1982–2004 (2023).

Article  PubMed  Google Scholar 

Khan, S. S. et al. Development and validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations. Circulation (2023).

Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).

Article  CAS  PubMed  Google Scholar 

Brosius, F. C. et al. Transforming the care of patients with diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 16, 1590–1600 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069–1084 (2023).

Article  CAS  PubMed  Google Scholar 

Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

Article  CAS  PubMed  Google Scholar 

Vyas, D. A., Eisenstein, L. G. & Jones, D. S. Hidden in plain sight - reconsidering the use of race correction in clinical algorithms. N. Engl. J. Med. 383, 874–882 (2020).

Article  PubMed  Google Scholar 

Waters, H. & Graf, M. America’s Obesity Crisis. The Health and Economic Costs of Excess Weight (Milken Institute, 2018).

AHA. Get With The Guidelines. heart.org, https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines (2024).